Key points from article :
Jupiter Neurosciences, a biotech firm focused on treating neuroinflammation, has raised $11 million through an IPO on Nasdaq under the ticker "JUNS." The funds will advance JOTROL, a resveratrol-based therapy, into Phase 2 clinical trials for Parkinson's disease. JOTROL is unique in delivering therapeutic resveratrol doses without gastrointestinal side effects, a breakthrough in resveratrol treatment.
Resveratrol, a natural compound with anti-inflammatory and anti-aging properties, has shown potential in preclinical studies to improve cognition, lower blood pressure, and boost heart health. JOTROL leverages resveratrol's benefits while overcoming bioavailability challenges. Phase 1 studies confirmed its safety, with no serious adverse effects.
Jupiter’s pipeline includes treatments for rare diseases, mild cognitive impairment, early Alzheimer’s, and traumatic brain injuries. Founded in 2015 and based in Jupiter, Florida, the company plans to use the IPO proceeds for Southeast Asia operations, R&D, licensing fees, debt repayment, and corporate growth.
